Study Evaluating the 24-Hour Pulmonary Function Profile of Fluticasone Furoate (FF) /GW642444 (Vilanterol) (VI) Inhalation Powder 100/25mcg Once Daily Compared With Fluticasone Propionate/Salmeterol Inhalation Powder 250/50mcg Twice Daily in Subjects With Chronic Obstructive Pulmonary Disease (COPD)

PHASE3CompletedINTERVENTIONAL
Enrollment

512

Participants

Timeline

Start Date

March 18, 2011

Primary Completion Date

January 1, 2012

Study Completion Date

January 24, 2012

Conditions
Pulmonary Disease, Chronic Obstructive
Interventions
DRUG

Fluticasone Furoate 100mcg/ GW642444 (vilanterol) 25mcg

inhalation powder

DRUG

Fluticasone Propionate 250mcg / salmeterol 50mcg

inhalation powder

DRUG

Double-dummy placebo

inhalation powder

DRUG

Salbutamol as needed

inhalation powder

Trial Locations (51)

1034

GSK Investigational Site, Witbank

1459

GSK Investigational Site, Reiger Park

1501

GSK Investigational Site, Benoni

6045

GSK Investigational Site, Port Elizabeth

6529

GSK Investigational Site, George

7130

GSK Investigational Site, Somerset West

7531

GSK Investigational Site, Bellville

7572

GSK Investigational Site, Cape Town

9301

GSK Investigational Site, Bloemfontein

14004

GSK Investigational Site, Córdoba

18009

GSK Investigational Site, Cherkassy

20089

GSK Investigational Site, Rozzano (MI)

21018

GSK Investigational Site, Vinnytsia

23552

GSK Investigational Site, Lübeck

24411

GSK Investigational Site, Ponferrada (León)

27003

GSK Investigational Site, Lugo

29118

GSK Investigational Site, Orangeburg

29303

GSK Investigational Site, Spartanburg

29340

GSK Investigational Site, Gaffney

29678

GSK Investigational Site, Seneca

32720

GSK Investigational Site, DeLand

35128

GSK Investigational Site, Padua

35501

GSK Investigational Site, Jasper

43100

GSK Investigational Site, Parma

45231

GSK Investigational Site, Cincinnati

47005

GSK Investigational Site, Valladolid

50134

GSK Investigational Site, Florence

54003

GSK Investigational Site, Mykolayiv

55402

GSK Investigational Site, Minneapolis

60126

GSK Investigational Site, Torrette (AN)

61002

GSK Investigational Site, Kharkiv

61035

GSK Investigational Site, Kharkiv

73103

GSK Investigational Site, Oklahoma City

78006

GSK Investigational Site, Boerne

80131

GSK Investigational Site, Napoli

81027

GSK Investigational Site, San Felice A Cancello Caserta

82037

GSK Investigational Site, Telese Terme (BN)

83099

GSK Investigational Site, Donetsk

83814

GSK Investigational Site, Coeur d'Alene

90146

GSK Investigational Site, Palermo

92506

GSK Investigational Site, Riverside

97504

GSK Investigational Site, Medford

00185

GSK Investigational Site, Rome

09126

GSK Investigational Site, Cagliari

0380

GSK Investigational Site, Thabazimbi

03114

GSK Investigational Site, Alicante

06800

GSK Investigational Site, Mérida (Badajoz)

03680

GSK Investigational Site, Kiev

03038

GSK Investigational Site, Kyiv

03049

GSK Investigational Site, Kyiv

04107

GSK Investigational Site, Kyiv

Sponsors

Lead Sponsor

All Listed Sponsors
lead

GlaxoSmithKline

INDUSTRY